

**Conclusion** The estimation of post-operative mortality risk is a crucial part of management of patients with NSCLC. Overall mortality following surgery for NSCLC in England is currently 3% at 30-days and 6% at 90-days. We present UK data, stratified by age and performance status, which could be used in clinical practise to assist with the estimation of early post-operative mortality risk.

**Abstract P202 Table 1** Proportion of patients who died within 90 days of lobectomy or pneumonectomy for NSCLC (*italics show total number of patients who underwent the procedure in each category; # no deaths occurred in these groups*)

Age	Performance status						
	0	1	2	3-4	0	1	2
<70	1% <i>1,611</i>	4% <i>974</i>	7% <i>160</i>	10% <i>30</i>	8% <i>307</i>	12% <i>205</i>	6% <i>31</i>
70-80	4% <i>831</i>	7% <i>833</i>	9% <i>128</i>	13% <i>30</i>	19% <i>106</i>	14% <i>94</i>	22% <i>18</i>
>80	7% <i>151</i>	6% <i>209</i>	24% <i>29</i>	# <i>4</i>	22% <i>9</i>	19% <i>16</i>	# <i>0</i>
	<i>LOBECTOMY</i>				<i>PNEUMONECTOMY</i>		

**P203 ADDRESSING LOW SURGICAL RESECTION RATES FOR NON SMALL CELL LUNG CANCER: LOCAL INTERVENTION TO ADDRESS HIGH LEVELS OF EMERGENCY PRESENTATIONS AT LATE STAGE SHOULD BE EFFECTIVE.**

doi:10.1136/thoraxjnl-2012-202678.264

EM Hadley. *Barking, Havering & Redbridge NHS Trust, London, UK*

**Introduction** The National Lung Cancer Audit is a benchmarking tool for cancer networks and individual MDT's. The national average resection rate for all lung cancer patients is 13.7%. The NLCA recommend that all MDTs with a resection rate for NSCLC below 14%, and for stage 1a-2b below 52% should be reviewed to ensure that patients are being offered appropriate access to thoracic surgical expertise.

In the 2011 report our MDT had a resection rate for NSCLC of 7.8%. In light of this a review of all cancer patients was carried out. **Results and discussion** The resection rate for stage 1a-2b NSCLC patients was 48% which is similar to the national average. However the number of patients presenting with operable stage 1a-2b disease was unusually low at 12%.

An in depth review of 18 patients with operable NSCLC showed that there were four patients that did not have a curative resection. Two were performance stage 3-4 at presentation, one had a tumour in an inoperable location and the fourth had significant comorbidities precluding surgery.

The opportunity for patients to be offered surgical treatment of stage 1a-2b NSCLC at this MDT is within national targets. However the low figure on the LUCADA data is due to an unusually high proportion of patients (88%) presenting with stage 3-4 disease. This is reflected locally where we also have very high rates of lung cancer presenting via emergency admissions, around 70%. The national average is around 30-40%, a figure which is already considered unacceptable.

**Conclusion** In order to improve the rate of curative resection and improves survival for our population the key intervention is to diagnose more NSCLC at an early stage. We need to target the local population to present early, and empower primary care to refer early. We will study the impact of the 2012 National Lung Cancer Awareness Programme with interest, although it is likely that a further local campaign targeted at our specific community may be needed if we are to turn around local resection rates.

**P204 FRACTIONATED CARBOPLATIN AND VINOEBINE FOR ELDERLY AND POOR PERFORMANCE STATUS PATIENTS WITH NSCLC**

doi:10.1136/thoraxjnl-2012-202678.265

J Maguire, S Datta, V Kelly, P Mbanu. *Liverpool Heart and Chest Hospital, Liverpool, UK*

Patients with advanced NSCLC who are elderly and/or have poor Performance Status are generally considered unsuitable for chemotherapy and usually excluded from the possible benefits of systemic treatment. The outlook for this group of patients is poor, with typical survival times of four months or less.

If a tolerable form of systemic chemotherapy could be identified for elderly and poor PS patients, this would enable consideration of active rather than supportive care, and might improve overall survival rates.

We have treated 110 patients who were either aged over 70; (16%, n=18), PS 2 or greater (36%, n=40) or both; (46%, n=52) with systemic chemotherapy using fractionated Carboplatin and Vinorelbine. Carboplatin was administered at AUC 2.5 on day 1 and day 8, with oral Vinorelbine 60 mg/m<sup>2</sup> on a 21 day cycle. 40 patients had Stage III and 68 had Stage IV disease. Prophylactic levofloxacin 500 mg daily was given from day 9 to 20 of each treatment cycle. Renal function for Carboplatin dosage was measured using EDTA clearance. 67 patients were aged 70 or greater, and 22 more than 80 years. 90 patients were PS 2 or 3 and 51 patients were both over 70 and had poor PS.

The average number of cycles given to each patient was 3. 7% of patients died within 30 days of receiving chemotherapy treatment. The median survival for the whole patient group was 7.5 months. 72% percent of patients lived for 6 months or longer from commencement of chemotherapy. 40% of patients lived 9 months or longer and 22% of patients lived for a year or longer after starting chemotherapy. There was a strong statistical correlation between response to chemotherapy and survival.

In conclusion, systemic chemotherapy using fractionated Carboplatin and Vinorelbine should be considered as a possible treatment option for patients with advanced NSCLC who are elderly or have moderate to poor PS.

**P205 SMOKING PREVALENCE AND SMOKING CESSATION AMONGST ACUTE MEDICAL ADMISSIONS**

doi:10.1136/thoraxjnl-2012-202678.266

R Harrison, P Preston, C Bucur, SV Fletcher. *University Hospital Southampton NHS Foundation Trust, Southampton, UK*

**Introduction and Objectives** In 2009/10 there were 1.5 million hospital admissions in adults aged >35yrs with a smoking related illness. Smoking cessation is a cost effective clinical intervention, producing better health outcomes for patients and saving NHS resources. In 2010/11 total expenditure on 'NHS Stop Smoking Services' in England excluding prescriptions was £84.3million. NICE guidelines recommend that every smoker should be offered smoking cessation advice and prescription of nicotine replacement therapy (NRT).

The purpose of this study was to identify smoking prevalence in a general medical inpatient population at the time of admission and evaluating the hospital's provision of smoking cessation advice and NRT prescription.

**Methods** Using a cross-sectional study design, contemporaneous data was collected from the Acute Medical Unit (AMU) on 6 separate days. All admitted patients were eligible and interviewed using a standardised questionnaire. Three interviewers agreed a standard approach to questioning. Contemporaneous hospital notes and drug charts were reviewed. Exclusions to the study included cognitive impairment, language, not being present on the ward, being significantly clinically unwell and patient refusal.